Form 4: Medtronic Executive Reports Equity Vesting

Medtronic EVP Harry Skip Kiil acquired 15,195 ordinary shares following the settlement of performance-vesting share units.

Summary

• Harry Skip Kiil, EVP & President of Cardiovascular at Medtronic, acquired 15,195 ordinary shares on May 26, 2026.
• The acquisition resulted from the settlement of performance-vesting share units granted on July 31, 2023.
• The reporting person now holds a total of 48,233 ordinary shares directly.
• The total includes 270 shares acquired through dividend reinvestment since the previous filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation rather than a market-moving strategic or financial update.

Positives

• The transaction reflects the successful vesting of performance-based equity incentives for a key executive.
• The executive maintains a significant direct ownership stake of 48,233 shares.

Negatives

• None identified; this is a standard equity compensation settlement.

Risks

• None identified; this is a standard equity compensation settlement.

Future Outlook

Not applicable as this is a retrospective disclosure of equity compensation.

Industry Context

StockSavvy.ai notes that executive equity settlements are routine corporate governance events and do not typically signal a change in strategic direction or market outlook for large-cap medical device companies like Medtronic.

Comparison to Industry Standards

• The equity compensation structure aligns with standard practices for S&P 500 healthcare companies.
• Performance-vesting units are a common retention tool used by competitors such as Abbott Laboratories and Boston Scientific.

Stakeholder Impact

• Minimal impact on shareholders as the transaction involves existing equity compensation plans.

Key Dates

Keywords

Medtronic, MDT, Form 4, Insider Trading, Equity Compensation, Performance Share Units